Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (61-70 of 148) with videos related to

Pageof 15
Sort By:
Current Medical Research and Opinion|November 19, 2010
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasisHind T Hatoum, Swu-Jane Lin, Amy Guo, et al.
Breast Cancer Research and Treatment|June 25, 2010
Prognostic factors for skeletal complications from metastatic bone disease in breast cancerJanet E Brown, Richard J Cook, Allan Lipton, et al.
Clinical Breast Cancer|June 14, 2011
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisHind T Hatoum, Swu-Jane Lin, Matthew R Smith, et al.
American Journal of Clinical Oncology|August 5, 2009
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastasesAllan Lipton, Cynthia Campbell-Baird, Harold Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trialsSuhail M Ali, Kim Leitzel, Allan Lipton, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
Cancer|September 1, 2007
Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseFred Saad, Allan Lipton, Richard Cook, et al.
Cancer|August 23, 2008
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseHind T Hatoum, Swu-Jane Lin, Mathew R Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2013
Reply to Araki et alAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Cancer Research|September 2, 2008
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitorLois Witters, Peggy Scherle, Steven Friedman, et al.
Pageof 15

Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
Current Medical Research and Opinion|November 19, 2010
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasisHind T Hatoum, Swu-Jane Lin, Amy Guo, et al.
Breast Cancer Research and Treatment|June 25, 2010
Prognostic factors for skeletal complications from metastatic bone disease in breast cancerJanet E Brown, Richard J Cook, Allan Lipton, et al.
Clinical Breast Cancer|June 14, 2011
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisHind T Hatoum, Swu-Jane Lin, Matthew R Smith, et al.
American Journal of Clinical Oncology|August 5, 2009
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastasesAllan Lipton, Cynthia Campbell-Baird, Harold Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trialsSuhail M Ali, Kim Leitzel, Allan Lipton, et al.
The Oncologist|October 5, 2007
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityAllan Lipton, Richard J Cook, Pierre Major, et al.
Cancer|September 1, 2007
Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseFred Saad, Allan Lipton, Richard Cook, et al.
Cancer|August 23, 2008
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseHind T Hatoum, Swu-Jane Lin, Mathew R Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2013
Reply to Araki et alAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Cancer Research|September 2, 2008
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitorLois Witters, Peggy Scherle, Steven Friedman, et al.
Pageof 15